CommercialCoverageMedium impact
Conversion of Anti-Coagulants to Heparin Before and After Elective Surgery (CPB 0200, reviewed 2026-03-25)
Aetna·Cardiology, Cardiothoracic Surgery, General Surgery +3 more·Surgery
Effective date
Mar 25, 2026
We identified it
Aug 12, 2026
Summary
Aetna's CPB 0200 policy (effective 2026-03-25) establishes medical necessity criteria for continuous intravenous heparin infusion when converting anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban, warfarin) before and after elective surgery. The policy allows up to 3 inpatient pre-procedure days when anti-coagulation must be maintained due to thrombotic risk. Billing teams must ensure proper coding and documentation for heparin infusion services and related anticoagulant monitoring.
Action Required
By 2026-03-25: Billing team must implement the following: (1) Update billing system to recognize J1642, J1643, J1644 (heparin injection codes) and S9336 (home infusion therapy code) as covered when criteria are met for anticoagulant conversion cases; (2) Ensure Z79.01 (long-term anticoagulant use) is documented on all claims involving heparin bridging therapy; (3) Require providers to document medical necessity for inpatient pre-procedure days (up to 3 days allowed) when anti-coagulation maintenance is clinically indicated—include risk assessment for thromboembolism vs. bleeding; (4) Train billing staff that pre-procedure weaning may be done outpatient in most cases, but inpatient admission is covered only when circumstances compromise anti-coagulation state; (5) Flag claims for audit if more than 3 inpatient pre-procedure days are billed; (6) Coordinate with clinical teams to ensure providers document which anticoagulant is being converted (apixaban, dabigatran, edoxaban, rivaroxaban, or warfarin) and the clinical justification for heparin bridging. Failure to obtain proper medical necessity documentation will result in claim denials.